Literature DB >> 26465127

Do Patients at Sites With High RCT Enrollment Propensity Have Better Outcomes?

Alistair J O'Malley1, Katya Zelevinsky, Yulei He, Alisa B Busch.   

Abstract

BACKGROUND: Concerns about randomized controlled trial (RCT) generalizability typically center on characteristics of RCT patient participants. Possibly there are RCT site characteristics that distinguish RCT outcomes from those that can be expected in non-RCT settings.
OBJECTIVES: To examine whether site propensity toward RCT enrollment is associated with recovery outcomes for patients and whether the association differs between patients who participate in a RCT compared with those who remain in an observational (OBS) treatment environment. DATA: Study participants with acute bipolar depression from The Systematic Treatment Enhancing Program for Bipolar Disorder acute depression pharmacotherapy RCT (N=337) and OBS treatment arm (N=1581).
METHODS: A longitudinal OBS study comparing the likelihood of recovery in the RCT to the OBS arm, allowing effect modification by site high RCT enrollment propensity (defined as >the median) and other predictors over a 6-month follow-up period.
RESULTS: Non-RCT participants who received care in sites with high RCT enrollment propensity had a higher probability of recovering from their bipolar-depression episode compared with participants from low propensity sites [odds ratio (95% confidence interval)=2.13 (1.28-3.55)]. RCT enrollment propensity was not associated with recovery outcomes for RCT participants [1.03 (0.35-3.03)].
CONCLUSIONS: Sites with high propensity to enroll patients in RCTs appear to have unobserved characteristics, which play a significant role in outcomes for non-RCT patients. For RCT participants in low-enrollment sites, possibly RCT protocols, which proscribe care delivery and monitoring, attenuate this effect. These results have implications for future research to improve outcomes in nonresearch care settings.

Entities:  

Mesh:

Year:  2015        PMID: 26465127      PMCID: PMC4672722          DOI: 10.1097/MLR.0000000000000429

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  11 in total

1.  A comparison of observational studies and randomized, controlled trials.

Authors:  K Benson; A J Hartz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

2.  Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research.

Authors:  Jonathan A C Sterne; Peter Jüni; Kenneth F Schulz; Douglas G Altman; Christopher Bartlett; Matthias Egger
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 3.  Epidemiologic analyses of causation: the unlearned scientific lessons of randomized trials.

Authors:  A R Feinstein
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

4.  The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description.

Authors:  R L Spitzer; J B Williams; M Gibbon; M B First
Journal:  Arch Gen Psychiatry       Date:  1992-08

5.  Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program.

Authors:  David J Miklowitz; Michael W Otto; Ellen Frank; Noreen A Reilly-Harrington; Stephen R Wisniewski; Jane N Kogan; Andrew A Nierenberg; Joseph R Calabrese; Lauren B Marangell; Laszlo Gyulai; Mako Araga; Jodi M Gonzalez; Edwin R Shirley; Michael E Thase; Gary S Sachs
Journal:  Arch Gen Psychiatry       Date:  2007-04

Review 6.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

Review 7.  Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD).

Authors:  Gary S Sachs; Michael E Thase; Michael W Otto; Mark Bauer; David Miklowitz; Stephen R Wisniewski; Philip Lavori; Barry Lebowitz; Mathew Rudorfer; Ellen Frank; Andrew A Nierenberg; Maurizio Fava; Charles Bowden; Terence Ketter; Lauren Marangell; Joseph Calabrese; David Kupfer; Jerrold F Rosenbaum
Journal:  Biol Psychiatry       Date:  2003-06-01       Impact factor: 13.382

8.  Effectiveness of adjunctive antidepressant treatment for bipolar depression.

Authors:  Gary S Sachs; Andrew A Nierenberg; Joseph R Calabrese; Lauren B Marangell; Stephen R Wisniewski; Laszlo Gyulai; Edward S Friedman; Charles L Bowden; Mark D Fossey; Michael J Ostacher; Terence A Ketter; Jayendra Patel; Peter Hauser; Daniel Rapport; James M Martinez; Michael H Allen; David J Miklowitz; Michael W Otto; Ellen B Dennehy; Michael E Thase
Journal:  N Engl J Med       Date:  2007-03-28       Impact factor: 91.245

9.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  Comparing hormone therapy effects in two RCTs and two large observational studies that used similar methods for comprehensive data collection and outcome assessment.

Authors:  Arthur Hartz; Tao He; Robert Wallace; John Powers
Journal:  BMJ Open       Date:  2013-07-15       Impact factor: 2.692

View more
  1 in total

1.  Clinicians' Perceptions of Rapid Scale-up of Telehealth Services in Outpatient Mental Health Treatment.

Authors:  Dawn E Sugarman; Lisa E Horvitz; Shelly F Greenfield; Alisa B Busch
Journal:  Telemed J E Health       Date:  2021-02-18       Impact factor: 3.536

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.